Trial Profile
Rosuvastatin Prevents Conduit Artery Endothelial Dysfunction Induced by Ischemia and Reperfusion by a Cyclooxygenase-2–Dependent Mechanism
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Apr 2010
Price :
$35
*
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Myocardial infarction; Myocardial reperfusion injury
- Focus Pharmacodynamics
- 11 Apr 2010 New trial record
- 09 Mar 2010 Results reported in the Journal of the Amercian College of Cardiology.